Brought to you by 
Genzyme acquires SangStat Medical for $596mm
Aug 2003
Executive Summary
In a deal that will significantly add to its portfolio of immune-mediated drugs and drug candidates, Genzyme Corp. is acquiring SangStat Medical (develops, sells treatments for autoimmune disorders, immunosuppression, hematology, and cancer) for $596mm in cash, or $22.50 per share (a 51% premium to the market average).
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Includes Contract
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme acquires SangStat Medical for $596mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice